For the quarter ending 2026-03-31, ALDX had -$5,038,949 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -3,452,619 | -6,461,507 | -7,688,341 | -19,696,813 |
| Stock-based compensation | -987,554 | 1,090,081 | 2,580,754 | 2,420,578 |
| Non-cash interest expense | 50,368 | 50,367 | 50,368 | 117,525 |
| Net amortization of premium on marketable securities | 0 | 44,075 | 266,560 | 838,915 |
| Depreciation and amortization expense | 66,599 | 65,116 | 63,683 | 123,194 |
| Write-off of deferred offering costs | 0 | 0 | 0 | 267,261 |
| Prepaid expenses and other current assets | -470,688 | -420,494 | -50,152 | -708,358 |
| Accounts payable | -17,105 | 145,038 | -1,016,107 | 849,077 |
| Accrued expenses and other liabilities | -1,240,466 | -564,859 | -795,365 | -4,975,186 |
| Net cash used in operating activities | -5,110,089 | -5,299,345 | -7,021,416 | -21,024,921 |
| Purchases of marketable securities | 0 | 0 | 0 | 40,263,712 |
| Maturities of marketable securities | 0 | 16,000,000 | 25,000,000 | 47,000,000 |
| Net cash provided by investing activities | 0 | 16,000,000 | 25,000,000 | 6,736,288 |
| Proceeds from issuance of common stock, net of issuance costs | - | - | 0 | - |
| Issuance costs | - | 0 | - | - |
| Proceeds from exercise of stock options | 71,140 | 0 | 120,746 | 983,194 |
| Proceeds from employee stock purchase plan | 0 | 0 | 0 | 19,616 |
| Debt end of term charge paid in cash | - | 0 | - | - |
| Net cash provided by financing activities | 71,140 | 0 | 120,746 | 1,002,810 |
| Net decrease in cash and cash equivalents | -5,038,949 | 10,700,655 | 18,099,330 | -13,285,823 |
| Cash and cash equivalents, beginning of period | 70,041,254 | 59,340,599 | 54,527,092 | - |
| Cash and cash equivalents, end of period | 65,002,305 | 70,041,254 | 59,340,599 | - |
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)